Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin resistance in human partial lipodystrophy.

R A Hegele1

  • 1Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 406-100 Perth Drive, London, Ontario, Canada N6A 5K8. robert.hegele@rri.on.ca

Current Atherosclerosis Reports
|December 21, 2000
PubMed
Summary

Rare Dunnigan-type familial partial lipodystrophy (FPLD) is caused by mutations in the LMNA gene. This genetic condition leads to insulin resistance and shares many features with common metabolic syndrome.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye.

Journal of clinical lipidology·2024
Same author

Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.

Journal of internal medicine·2019
Same author

Conservative management in hypertriglyceridemia-associated pancreatitis.

Journal of internal medicine·2019
Same author

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.

BMC neurology·2019
Same author

Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a).

Journal of thrombosis and haemostasis : JTH·2017
Same author

Atypical Presentation and Treatment Response in a Child with Familial Hypercholesterolemia Having a Novel LDLR Mutation.

JIMD reports·2016

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Cell Biology

Background:

  • Insulin resistance is common in obesity, presenting with glucose intolerance, dyslipidemia, and hypertension.
  • Dunnigan-type familial partial lipodystrophy (FPLD) is a rare genetic disorder characterized by fat loss, insulin resistance, and metabolic abnormalities.
  • FPLD is linked to mutations in the LMNA gene, which encodes nuclear lamins A and C.

Purpose of the Study:

  • To investigate the phenotypic characteristics and early disease progression in FPLD patients with LMNA mutations.
  • To explore the relationship between nuclear structural defects and the development of insulin resistance and related metabolic disorders.

Main Methods:

  • Analysis of extended pedigrees with FPLD.
  • Clinical and biochemical evaluation of affected individuals.

Related Experiment Videos

  • Genetic analysis of LMNA gene mutations.

    • Main Results:

    • Dyslipidemia precedes glucose abnormalities in FPLD patients with LMNA mutations.
    • Hyperinsulinemia is an early feature of the disease.
    • Reduced plasma leptin levels are observed in FPLD patients with LMNA mutations.
    • Mutations in nuclear structural proteins can cause phenotypes resembling common insulin resistance syndrome.

    Conclusions:

    • Mutations in the LMNA gene can lead to a distinct form of partial lipodystrophy with significant metabolic derangements.
    • Nuclear envelope structure and function are critical for maintaining metabolic homeostasis.
    • FPLD serves as a model for understanding the pathogenesis of insulin resistance and related conditions.